Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

NCT04068168 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04068168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 30, 2020
Completion date
December 27, 2024
Enrollment
712 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, biliary tract cancer